Cytokinetics Inc vs Synchrony Financial — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Synchrony Financial trades at $78.37 (market cap $25.53B). The key difference: Synchrony Financial is far larger — about 2.4× Cytokinetics Inc's market cap, and Synchrony Financial pays a 1.73% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SYF | |
|---|---|---|
Market Cap | $10.63B | $25.53B |
Sector | Technology | Financials |
52-Week High | $87.26 | $88.47 |
52-Week Low | $34.31 | $63.78 |
Enterprise Value | $10.74B | — |
Dividend Yield | — | 1.73% |
Trailing returns across standard periods
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →